FDA Grants Regular Approval to Blinatumomab and Expands Indication to Include Philadelphia Chromosome-Positive B Cell ALL

U.S. Food and Drug Administration


On July 11, 2017, the U.S. Food and Drug Administration approved blinatumomab (Blincyto®, Amgen Inc.) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

View Article @ voice.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles